Alibhai Imran Nizamudin 4

What Happened
Alibhai Imran Nizamudin, CEO of Tvardi Therapeutics, was granted a derivative award covering 115,000 shares on January 29, 2026. The Form 4 records an acquisition (Code A) of 115,000 derivative shares at $0.00 (no cash paid at grant). This was an award/option-style grant subject to vesting rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-29; Form 4 filed: 2026-02-02.
• Transaction type: Grant/Award (derivative) — 115,000 shares; reported price $0.00.
• Vesting: Per footnote F1, shares vest in equal monthly installments over 48 months commencing January 29, 2026, subject to continuous service.
• Shares owned after transaction: Not specified in the supplied filing.
• Timeliness: Filing date provided; the report does not indicate a late filing flag in the supplied data.

Context
This entry reflects an equity compensation grant (derivative/option-like award) to the CEO. Such awards typically vest over time and do not represent an immediate cash purchase or sale; eventual exercises or sales would generate different signals. The vesting schedule means ownership will accrue gradually if the CEO remains in service.